pHion to progress its lead program into the clinic
invoX Pharma, a UK-based wholly-owned subsidiary of Sino Biopharmaceutical, with an advancing pipeline of innovative products, has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company. pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. Read More